Search - tctmd.com

Displaying 281 - 300 of 636

Sort: Relevancy | Date

Presentation TCT 2016

Case Presentation: BTK Intervention in Critical Limb Ischemia

Presenter: Bagrat Alekyan, Grzegorz L. Kaluza, Zaza Kavteladze

November 01, 2016

Presentation TCT 2016

Think Twice: BRS First

Presenter: George D. Dangas, Fabio Felice Tarantino, Francesco Saia

November 01, 2016

Presentation TCT 2016

How Would I Treat? (Option 2)

Presenter: Runlin Gao, Bo Xu, Qi Zhang

November 01, 2016

Presentation TCT 2016

Editorial Comment: Current Guidelines, Device, and Anticoagulation Strategies

Presenter: Bagrat Alekyan, Grzegorz L. Kaluza, Thomas D. Stuckey

November 01, 2016

Presentation TCT 2016

How Would I Treat? (Option 1)

Presenter: Runlin Gao, Bo Xu, Jian Liu

November 01, 2016

Presentation TCT 2016

Choose a Drug-Eluting Stent: Heres Why

Presenter: George D. Dangas, Fabio Felice Tarantino, Carlo Cernetti

November 01, 2016

Presentation TCT 2016

Case Introduction: How Should I Treat?

Presenter: Runlin Gao, Bo Xu, Junjie Zhang

November 01, 2016

Presentation TCT 2016

Case Introduction: What Device(s) to Choose in a Patient With NSTE-ACS?

Presenter: George D. Dangas, Fabio Felice Tarantino, Massimo Fineschi

November 01, 2016

Presentation TCT 2016

Case Presentation: Complex PCI in STEMI and Cardiogenic Shock

Presenter: Bagrat Alekyan, Grzegorz L. Kaluza, Vladimir Ganyukov

November 01, 2016

Presentation TCT 2016

Case Conclusion: How Did I Treat?

Presenter: Runlin Gao, Bo Xu, Kefei Dou

November 01, 2016

Presentation TCT 2016

Case Conclusion: How Did We Treat Our Patient?

Presenter: Roxana Mehran, Ferdinando Varbella, Alberto Menozzi

November 01, 2016

Presentation TCT 2016

Case Presentation: LAA Intervention in the TAVR Patient

Presenter: Bagrat Alekyan, Grzegorz L. Kaluza, Alexey Protopopov

November 01, 2016

Presentation TCT 2016

Intravenous P2Y12 Receptor Inhibitors Transitioning to a Potent Oral Anti-platelet Agent if PCI Is Performed Is Optimal Treatment in NSTE-ACS

Presenter: Roxana Mehran, Ferdinando Varbella, Dominick J. Angiolillo

November 01, 2016

Presentation TCT 2016

How Would I Treat? (Option 2)

Presenter: Runlin Gao, Bo Xu, Zening Jin

November 01, 2016

Presentation TCT 2016

How Would I Treat? (Option 1)

Presenter: Runlin Gao, Bo Xu, Philippe Généreux

November 01, 2016

Presentation TCT 2016

To Pretreat or Not to Pretreat? The DUBIUS Trial

Presenter: Roxana Mehran, Ferdinando Varbella, Giuseppe Tarantini

November 01, 2016

Presentation TCT 2016

Case Introduction: How Should I Treat?

Presenter: Runlin Gao, Bo Xu, Kefei Dou

November 01, 2016

Presentation TCT 2016

Case Introduction: An Elderly Patient With NSTE-ACS

Presenter: Roxana Mehran, Ferdinando Varbella, Alberto Menozzi

November 01, 2016

Presentation TCT 2016

Case Presentation: ACS Intervention in the Emerging BRS Era

Presenter: Bagrat Alekyan, Grzegorz L. Kaluza, Evgeny V. Merkulov

November 01, 2016

News Conference News TCT 2016

Midterm Durability of TAVR Valves: PARTNER, Other Studies Boost Confidence

Todd Neale

November 01, 2016

Advertisement

Case Presentation: BTK Intervention in Critical Limb Ischemia

Think Twice: BRS First

How Would I Treat? (Option 2)

Editorial Comment: Current Guidelines, Device, and Anticoagulation Strategies

How Would I Treat? (Option 1)

Choose a Drug-Eluting Stent: Heres Why

Case Introduction: How Should I Treat?

Case Introduction: What Device(s) to Choose in a Patient With NSTE-ACS?

Case Presentation: Complex PCI in STEMI and Cardiogenic Shock

Case Conclusion: How Did I Treat?

Case Conclusion: How Did We Treat Our Patient?

Case Presentation: LAA Intervention in the TAVR Patient

Intravenous P2Y12 Receptor Inhibitors Transitioning to a Potent Oral Anti-platelet Agent if PCI Is Performed Is Optimal Treatment in NSTE-ACS

How Would I Treat? (Option 2)

How Would I Treat? (Option 1)

To Pretreat or Not to Pretreat? The DUBIUS Trial

Case Introduction: How Should I Treat?

Case Introduction: An Elderly Patient With NSTE-ACS

Case Presentation: ACS Intervention in the Emerging BRS Era

Midterm Durability of TAVR Valves: PARTNER, Other Studies Boost Confidence

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content